Ultragenyx Pharmaceutical Inc at Barclays Global Healthcare Conference Transcript
Hi, everyone. Good afternoon. Welcome to Miami. I'm Ellie Merle, one of the biotech analysts here at Barclays. Very happy to have Ultragenyx here with us for a fireside chat.
And joining us from Ultragenyx is Dr. Eric Crombez, the Chief Medical Officer and EVP. Eric, thank you so much for joining us.
Questions & Answers
Well, it's an exciting year for the company heading into the Angelman Phase III. But before we dive into that, maybe just to start off with as a commercial stage rare disease biotech, could you provide a high-level overview of the story?
Yes. Great. And thanks for having me. Great to be here. So just very briefly, founded in 2010, public in 2014. Founded by our current CEO, Emil Kakkis, with a real focus on rare disease and focusing on patients and diseases where there still remains a high level of unmet medical need.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
